Accelerated Development of a Scalable Ring-Closing Metathesis to Manufacture AMG 176 Using a Combined High-Throughput Experimentation and Computational Modeling Approach | Organic Process Research & Development
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Accelerated Development of a Scalable Ring-Closing Metathesis to Manufacture AMG 176 Using a Combined High-Throughput Experimentation and Computational Modeling Approach | Organic Process Research & Development
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases - eBioMedicine
AMGEN at SITC
Clinical Trials and New Therapies for Multiple Myeloma | The MMRF
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
AMG 176 | New Drug Approvals
Amgen halts trials on cardiac toxicity | Evaluate
Targeting MCL-1 in cancer: current status and perspectives | Journal of Hematology & Oncology | Full Text
StudyPages - First in-Human Trial of the Experimental Drug AMG 176 in Relapsed or Refractory (re-occurring) Cancer of the Blood Systems
Cancers | Free Full-Text | Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
AMG-176 | Cas# 1883727-34-1 - GlpBio
AMG176 - Multiple Myeloma Clinical Trials
AstraZeneca Cancer Trial Hit with Clinical Hold Following Cardiac Issues | BioSpace
AMG 176 Myeloma Trials
AMG 176 | New Drug Approvals
PDF) Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Accelerated Development of a Scalable Ring-Closing Metathesis to Manufacture AMG 176 Using a Combined High-Throughput Experimentation and Computational Modeling Approach | Organic Process Research & Development
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation - ScienceDirect